PetLife Pharmaceuticals Announces Haiti Veterinary Initiative

PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high- potency veterinary cancer medications and nutraceuticals for pets, through its subsidiary, PetLife Pharma International, Inc. (collectively “PetLife”), and in cooperation with Elite International Partners (“Elite”), announces its initiatives in Haiti to improve the lives of companion animals and the people of Haiti. With the cooperation and support of the Haitian government, and in partnership with the Mission Light of Light Church, PetLife is establishing a scorpion ranch and laboratory facilities (“PetLife Scorpion Ranch” ™), to harvest the venom of the Caribbean Blue Scorpion. This effort will provide the necessary material for PetLife’s research efforts and production of its patent- pending formulation for the treatment of cancer in animals and humans.

PetLife’s formulation has been developed to address a leading cause of death in companion animals, one that causes the death of 47 percent of dogs and 32 percent of cats in the United States. We anticipate that a successful clinical trial in animals will not only relieve suffering in our companion pets but also will be the foundation for treatment of select human cancers. PetLife plans to proceed with the development of human applications after completion of our clinical and regulatory program which will be presented to the Food and Drug Administration (“FDA”) for approval soon. Once the program has been approved for implementation, PetLife anticipates that it will take approximately 24 months for the studies necessary for approval of the new animal drug which has been trademarked as VitalzulTM.

Our CEO, Dr. Ralph Salvagno, an Orthopaedic Surgeon, was part of the early medical teams that cared for victims of the earthquake in 2010. Returning several times since, he recognized the need for sustainable economic growth. PetLife is pleased to be part of the revitalization of the country of Haiti. As part of our new presence in Haiti, we are hosting a veterinary event with the aim of reducing the rapid spread of rabies in Haiti, which is the result of the earthquake. Haiti has the highest rate of human rabies deaths in the western hemisphere.

PetLife is working with the Mission Light of Light Church and the Haitian Government to establish a charitable foundation to benefit the orphans, workers and families who live nearby to our PetLife Scorpion Ranch™ and laboratory. As part of our long-term plan, we hope to establish a school, living quarters and medical facilities to the impoverished area.

About PetLife Pharmaceuticals

PetLife Pharmaceuticals, Inc. (PTLF) ( is a registered U.S. Veterinary Pharmaceutical company. PetLife’s mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, Vitalzul™, is currently in testing. Vitalzul™’s active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife’s acquired brand, Dr. Geoff’s Real Food for Pets, will launch in 2017. PetLife Scorpion Ranch™ will break ground in 2017. PetLife anticipates incorporating Vitalzul™ in a new and advanced therapeutic pet food line in 2019.

Forward-looking statement:

This press release contains certain "forward-looking statements," as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact

Dr. Ralph Salvagno
844-473-8543 ext. 702

Source: PetLife Pharmaceuticals, Inc.